The Director


Grants Awards and Contracts

  • Detection of Viral Genetic Information in ALS
    The ALS Association, National ALS Association & NINCDS
    $400,000/  1980-1984             
  • The Treatment of Familial Amyotrophic Lateral Sclerosis
    Skaggs Clinical Scholar Award
    Scripps Research Institute
    $240, 000/  2000-2003
  • Investigator Award
    Isis Pharmaceutical Corporation
    $360,000/  2004-2006   
  • Toxicology and Phase 1 Studies of Antisense ISIS 33611 in Familial ALS
    Muscular Dystrophy Association
    Tim Miller, P.I.,
    R Smith, Project Manager
    $1,030,000/  2007-2011        
  • The Treatment of Familial Amyotrophic Lateral Sclerosis with Antisense oligonucleotides
    Amyotrophic Lateral Sclerosis Association
    Co-Investigator with Merit Cudkowitz
    $300.000/   2011-2012                   
  • The Treatment of Bulbar Dysfunction in ALS
    MGH/.NEALS and the ALS Association
    $625,000/   2013-2014

Education and Experience

  • 1958-1961 Brandeis University, Waltham, MA.
  • 1961-1965 Univ. of Miami, School of Medicine, Miami, FL.
  • 1965-1966 Internship (Medicine), Jackson Memorial Hospital, Miami, FL.
  • 1966-1969 Residency (Neurology), Stanford, University Hospital, Palo Alto, CA.
  • 1969-1971 Lt. Commander, U.S. Navy, Head, Neurology Branch, Navy Neuropsychiatric Research Unit, San Diego, CA.
  • 1972-1979 Associate Staff - Neurology* & Microbiology, Scripps Clinic and Research Foundation, La Jolla, CA.
  • 1980-2005 Senior Medical Staff, Scripps Memorial Hospital, La Jolla, California
  • 1979-Present Director, Center for Neurologic Study, La Jolla, CA.
  • 1998-Present Principal Investigator/Sub-Investigator, Coordinated Clinical Research, La Jolla, CA.
  • 1999-2008 Skaggs Clinical Scholar, Scripps Research Institute, La Jolla, CA.
  • 2000-2008 Visiting Scholar, Department of Neuroscience, University of California, San Diego - School of Medicine, La Jolla, CA.  
  • 2005-Present Honorary Medical Staff, Scripps Memorial Hospital, La Jolla, CA.



  • Henry Newman Award - 1968 (San Francisco Neurologic Society)
  • Skaggs Clinical Scholar - 1999-2001 (Scripps Clinic and Research Foundation)
  • Essey Award - 2014 (ALS Association) 


Professional Societies



  • Method for Enhancing the Systemic Delivery of Dextromethorphan for the treatment of Neurological Disorders (5,166,207).
  • Method for Reducing Emotional Lability in Neurologically Impaired Patients (5,206,248).
  • Use of a Cytochrome Oxidase Inhibitor to Increase the Cough-Suppressing Activity of Dextromethorphan (5,350,756).
  • Dextromethorphan and Oxidase Inhibitor for Weaning Patients from Narcotics and Anti-Depressants (6,207,674)
  • Use of Dextromethorphan and an Oxidase Inhibitor to Treat Dermatitis (5,366,980)
  • Dextromethorphan and an Oxidase Inhibitor for Treating Intractable Conditions (5,863,927)
  • Antisense Modulation of Superoxide Dismutase 1, Soluble (SOD-1) Expression (7,678,895)
  • Modulation of Transthyretin Expression for the Treatment of CNS Related Disorders (filed).
  • The Treatment of Motor and Mental Function with Sigma 1 agonists (filed)